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(STEMI)Background: The aim of this clinical research was to investigate the effects of Pressure-controlled inter-
mittent Coronary Sinus Occlusion (PiCSO) on infarct size at 5 days after primary percutaneous coronary
intervention (pPCI) in patients with ST-segment elevation myocardial infarction (STEMI).
Methods and results: This comparative study was carried out in four UK hospitals. Forty-five patients with
anterior STEMI presenting within 12 h of symptom onset received pPCI plus PiCSO (initiated after reper-
fusion; n = 45) and were compared with a propensity score-matched control cohort from INFUSE-AMI
(n = 80). Infarct size (% of LV mass, median [interquartile range]) measured by cardiac magnetic reso-
nance (CMR) at day 5 was significantly lower in the PiCSO group (14.3% [95% CI 9.2–19.4%] vs. 21.2%
[95% CI 18.0–24.4%]; p = 0.023). There were no major adverse cardiac events (MACE) related to the
PiCSO intervention.
Conclusions: PiCSO, as an adjunct to pPCI, was associated with a lower infarct size at 5 days after anterior
STEMI in a propensity score-matched population.
 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The treatment of choice for patients with acute ST-segment ele-
vation myocardial infarction (STEMI) is primary percutaneous
coronary intervention (pPCI), performed as quickly as possible
[1,2]. However, despite substantial improvements in survivalamong patients with STEMI [3] attributable to increased use of
reperfusion therapy and appropriate adjunct pharmacotherapy,
30-day mortality rates among those who have undergone pPCI
remain approximately 3–4% [3,4]. Despite the ability of pPCI to
restore epicardial reperfusion in approximately 90% of patients,
infarct size is often substantial, leading to increased heart failure
and increasedmortality [5]. Infarct size determinedwithin 1month
after pPCI has been strongly correlated with all-cause mortality
and hospitalization for heart failure.
Pressure-controlled intermittent Coronary Sinus Occlusion
(PiCSO) is a mechanical catheter-based device placed into the coro-
nary sinus after initial pPCI which intermittently increases mean
coronary sinus pressure and coronary sinus pulse pressure [6]. Pre-
vious experimental and human research have reported potential
beneficial effects of PiCSO on cardiac function [7,8] and infarct size
[9,10]. We therefore evaluated the effects of PiCSO as an adjunct to
pPCI on infarct size and myocardial function in patients with ante-
rior STEMI.
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2.1. Study design
This study was a prospective, parallel-cohort, comparative
study (clinicaltrials.gov identifier NCT02197325) that was carried
out between 13/1/2015 and 26/10/2017 in four centers in the UK
(Freeman Hospital, Newcastle-upon-Tyne; St. Bartholomew’s
Hospital, London; Liverpool Heart and Chest Hospital, Liverpool;
and Northern General Hospital, Sheffield). Consecutive patients
with anterior STEMI were treated with pPCI plus PiCSO if a
PiCSO-trained physician was available. The control group consisted
of patients with anterior STEMI at the same centers admitted when
a PiCSO-trained physician was not available.
The study protocol was approved by the ethics committee (14/
NE/1129) and conducted in accordance with the 2013 declaration
of Helsinki, the International Conference on Harmonization guideli-
nes onGoodClinical Practice, and ISO14155.As treatmentwas time-
critical, initial assent was verbal (witnessed and documented).
Within24hpost treatment, patientswere givenwritten information
about the study and written informed consent was obtained.
2.2. Patients
Tobe included in the study all of the followingconditionshad to be
present: first occurrence of STEMI; culprit lesion in the left anterior
descending artery; and age  25 years. Patients were excluded for
any of the following: complicated pPCI (i.e. angioplasty followed by
stent placement or direct stenting with adverse event(s) that would
preclude the use of PiCSO, including major bleeding, perforation,
hypotension, pulmonary edema, or clinical instability; symptom
onset time > 12 h; previous coronary artery bypass graft surgery; his-
toryof stroke, transient ischemic attack, or reversible ischemicneuro-
logical disease within the past 6 months; hospitalization with a
primary diagnosis of acute myocardial infarction previously or evi-
dence of previousQ-wave infarct; known contraindication for cardiac
magnetic resonance imaging (CMR); active or treatedmalignancies in
the previous 12 months; pregnancy; non-cardiac comorbidities and
life expectancy <1 year; and use of warfarin.
2.3. PiCSO treatment
The PiCSO Impulse System (Miracor Medical SA, Awans, Bel-
gium) consists of a console which is controlled by a graphical user
interface and a single-use balloon catheter. The catheter contains
four lumens, a balloon on the distal end, and soft tip and connec-
tors on the proximal end for the shuttle gas supply and coronary
sinus pressure measurement. The system saves a log file for each
patient from which the device performance can be determined,
i.e. increase in coronary sinus pressure during inflation cycles.
In the current study qualifying patients with anterior STEMI
were treated with PiCSO in adjunct to standard PCI if a suitably-
trained PiCSO operator was present, otherwise the patients have
undergone a standard PCI. PiCSO therapy was started immediately
after successful flow restoration in the occluded LAD by balloon
angioplasty or aspiration, but before stent insertion. PiCSO was
then provided during stenting and for at least 20 min thereafter.
Treatment was continued until a PiCSO Quantity (sum of modula-
tion of coronary sinus pressure during occlusion phase over the
time [9]) of 800 mmHg was reached.
2.4. Assessments and follow-up
Follow-up in STEMI patients was performed at 5 ± 2 and
120 ± 14 days after pPCI for adverse event assessment and perfor-mance of CMR. All data were entered in an electronic database
(EDC2GO, Genae, Antwerp, Belgium). Blinded analysis of the CMR
scans was performed by an independent core laboratory (VU
University Medical Center, Amsterdam, the Netherlands). Blinded
quantification of pre- and post-pPCI Thrombolysis In Myocardial
Infarction (TIMI) flow was performed by an independent angio-
graphic core laboratory (Cardialysis, Rotterdam, Netherlands). An
independent clinical events committee adjudicated all safety
events. The data were independently monitored by Genae. MACE
was defined as a composite of cardiac death, new or worsening
hospitalization for heart failure, target vessel revascularisation,
stroke, major bleeding (BARC 3–5) or coronary sinus damage
requiring intervention. Propensity score matching was performed
by independent statisticians at the Cardiovascular Research Foun-
dation (New York, NY, USA).2.5. Statistical analysis
Descriptive statistics are given as means with standard devia-
tions (SD) or medians (interquartile range) for continuous variables
and counts and percentages for categorical variables. PiCSO and
control groups were compared using the two-sample t-test or
Mann Whitney U test for continuous variables and Fisher’s exact
or Pearson’s chi square test for categorical variables. All statistical
analyses were performed using SPSS, Version 24.0 (IBM Corp.,
Armonk, NY, USA).
As the baseline characteristics of the PiCSO and parallel groups
varied (Supplementary Table 1), PiCSO-treated patients were also
compared with a propensity-matched control cohort of patients
from INFUSE-AMI [11,12] who had CMR data at 5 days and did
not receive intracoronary abciximab (control group). PiCSO-
treated patients meeting the eligibility criteria were matched on
sex, age, diabetes, culprit lesion location (proximal vs. mid left
anterior descending artery), symptom-to-balloon time, pre-pPCI
TIMI flow (0/1 vs. 2/3), and post-pPCI TIMI flow (2 vs. 3). Each
PiCSO-treated patient with available 5-day post-MI infarct size
was matched to three control patients from INFUSE-AMI
(calliper = 0.5  SD of propensity score). PiCSO patients who could
not be adequately matched were excluded. While the propensity
matching has been performed by one statistician blinded to infarct
size measurements, the efficacy analysis has been performed by a
second statistician. Infarct size at day 5 was chosen as the endpoint
for this analysis as it has been widely used in clinical studies
[10,11,13–15] and has been strongly associated with all-cause
mortality and heart failure hospitalization [5].
As an additional analysis, MACE rates at 30 days were evaluated
in PiCSO-treated patients meeting the eligibility criteria in whom
at least 23 days of follow-up was present or earlier MACE had
occurred. This rate was compared to an objective performance goal
for 30-day MACE of 10% based on outcomes from the AMIHOT I/II,
CRISP and INFUSE-AMI studies. Based on binomial distribution
assessment this objective performance goal would be met if out
of 40 patients having valid 30-day follow-up less than 7 patients
had a MACE event.3. Results
3.1. Patients
A total of 92 patients were enrolled into the study. Among
those, 45 underwent pPCI with PiCSO and 47 underwent pPCI alone
(Supplementary Table 1 and Fig. 1).
PiCSO was initiated in 43/45 STEMI patients (95.6%); in two
STEMI patients difficulty obtaining femoral vein access (n = 1)
and the inability to cannulate the coronary sinus (n = 1) precluded
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stenting (i.e. per the protocol) in 35/43 STEMI patients (81.4%) and
after stenting in the remainder of the patients due to longer times
needed for cannulating the coronary sinus (12 ± 8 min for pre-
stenting start vs 22 ± 15 for post stenting start). Patients have
received PiCSO treatment on average for 33 ± 19 min and have
reached mean PiCSO quantity of 757 ± 301 mmHg. CMR was per-
formed in 34 PiCSO patients (at mean 5.2, SD 2.4 days) and the
infarct size was analyzable in 26 patients.
The 26 PiCSO patients treated were compared with 80 control
patients from INFUSE-AMI [11,12] study. Patients were matched
on sex, age, pre-PCI TIMI flow (0/1 vs 2/3), post PCI TIMI flow (2
vs 3), diabetes mellitus, culprit lesion location (proximal vs mid
LAD), and symptom to balloon time. After propensity score match-
ing 1 patient from the PiCSO study to a possible 3 patients from
INFUSE-AMI with a caliper of ½ the standard deviation of the
propensity score, 22 PiCSO patients and 56 INFUSE-AMI remained.
Finally, 40 PiCSO patients were available for the 30-day MACE
rate analysis; 5 patients withdrew from the study within 7 days.3.2. Efficacy results
The initial analysis comparing efficacy results of the PiCSO
group to the parallel control group reviewed that though the Area
at Risk has been comparable between the 2 groups, the infarct size
was consistently lower in the PiCSO vs. parallel control group at
5 days (13.99 ± 12.79 vs. 17.10 ± 11.72). Nevertheless, the differ-
ences were not statistically significant (p = 0.242) (Supplementary
Table 3). Although the mean microvascular obstruction among all
patients was similar, numerically fewer patients in the PiCSO
group had microvascular obstruction (26.9% vs. 46.7%; p = 0.17)
when compared to the parallel control group. Left ventricular ejec-
tion fraction was numerically better in the PiCSO group vs. parallel
control group at day 5, but not statistically significantly different
(50.5% vs. 46.8%; p = 0.076).
In order to account for the potential selection bias and the dif-
ferences in baseline characteristics between the PiCSO group and
parallel control group, the baseline characteristics of 22 per proto-
col PiCSO-treated patients were well matched with 56 INFUSE-AMI
patients (Table 1). Infarct size (% LV mass) at 5 days was smaller in
those anterior STEMI patients treated with PiCSO compared with
the propensity-matched controls (mean 14.3% vs. 21.2%; mean dif-
ference 6.9% (95% confidence interval [CI] 12.9 to 0.9%;
p = 0.023) (Fig. 2). The ejection fraction (50.8 vs. 47.1, p = 0.136),
left ventricular end systolic volume (42.5 vs. 48.1, p = 0.183) and
left ventricular end diastolic volume (50.8 vs. 47.13, p = 0.136)
did not differ in this analysis at 5 days between the PiCSO treated
patients and the propensity matched control patients.3.3. Safety results
Five MACE events occurred during the course of this study; as
listed in Supplementary Table 2. Three were cardiac deaths and
one new onset of heart failure in the PiCSO group. In addition,
one patient in the parallel control group has developed new onset
of heart failure. None of these events were adjudicated as
procedure- or device-related. Among PiCSO-treated STEMI patients
with 30-day follow-up (n = 40), MACE occurred in 4 patients
(10.0%), below the threshold for the objective performance goal
(Table 2). In a tipping point analysis, at least 3 of these 5 patients
(60%) would need to have a 30-day MACE in order for the study
to be considered a failure for safety. Between 30 days and the last
follow-up visit (120 days) no additional MACE occurred.4. Discussion
4.1. Main findings
Infarct size assessment within the first 30 days post myocardial
infarction has been widely used as an efficacy endpoint in clinical
studies of reperfusion therapy in STEMI as it is strongly associated
with all-cause mortality and heart failure hospitalization (5, 10, 11,
13–15). In the current study qualifying patients with anterior
STEMI were treated with PiCSO in adjunct to standard PCI if a
suitably-trained PiCSO operator was present, otherwise the
patients have undergone a standard PCI. Due to the non-
randomized nature of the treatment allocation the baseline charac-
teristics of the two groups (PiCSO group and parallel control group)
were quite different, most notably that patients in the PiCSO group
had better pre-PCI TIMI flow than patients in the control group. As
better pre-PCI TIMI flow has been strongly correlated with smaller
infarct size [16], we hypothesized that this may have accounted for
the smaller infarct size in the PiCSO group. Therefore, we compared
the PiCSO patients with propensity-matched controls from the
INFUSE-AMI trial [11,12]. In this analysis of patients with a first
anterior STEMI undergoing pPCI, treatment with PiCSO after initial
reperfusion resulted in a significant decrease in infarct size at
5 days compared to a propensity-adjusted control population from
the INFUSE-AMI trial.4.2. Timing of PICSO and its relationship to salvage and the mode of
action
Myocardial salvage is the paramount objective of PCI. Despite
improvements in the reperfusion techniques and optimized work-
streams, the mortality of STEMI patients has plateaued over the
past decade [17]. The incomplete recovery post PCI due to under-
lying pathophysiology of reperfusion and clinical consequences of
microcirculatory obstruction might be one of the reasons for such
stagnation.
During myocardial infarction the size of the myocardial necrosis
extends antegrade from the culprit lesion and stretches to the
peripheral border zones. If the Area at Risk is too large to be per-
fused with collateral or diffusive blood flow, the size of infarction
would be greater leading also to a greater area of microvascular
obstruction [18].
Today, there is no doubt that the ‘‘Time is Muscle” principle
positively alters the severity and extent of myocardial ischemic
injury. Deferred-stenting strategy alone when compared with
immediate stenting has not been able to reduce the occurrence
of no- or slow-reflow during pPCI, nor has it influenced the mortal-
ity [19]. Since with PiCSO we are aiming to facilitate the washout
first and clear the microcirculation, deferring stenting to post
PiCSO start could allow ‘‘preparing” the deprived myocardial areas
for the next wave injury caused stenting [20].
During reperfusion and revascularization induced injury, the
coronary venous drainage system may play an integral part in
accessing the obstructed microvasculature, paving the path to
new therapies like PiCSO allowing for retro-perfusion of the
deprived myocardium as well as simultaneous washout of debris
and toxic accumulations [20].
During occlusion of the coronary sinus by PiCSO Impulse Cathe-
ter, the venous pressure increases gradually until the systolic peaks
reach a plateau (which differs from patient to patient as well as
within the procedure based on the physiological state and impair-
ment grade of the coronary flow) resulting in an accumulation of
blood in the venous bed and an increase of diastolic coronary sinus
pressure. The additional input of blood during systole causes a fur-
ther distension and thus systolic pressure elevation in the coronary
Fig. 1. Study flow diagram. CMR: cardiac magnetic resonance imaging; PiCSO: Pressure-controlled intermittent Coronary Sinus Occlusion; pPCI: primary percutaneous
coronary intervention; STEMI: ST-segment elevation myocardial infarction.
Table 1
Baseline characteristics and CMR timing of PiCSO-treated patients compared with a
propensity-matched control group from the INFUSE-AMI trial.
PiCSO
(n = 22)
INFUSE-AMI Control
(n = 56)
p-
value
Men 16 (72.7) 41 (73.2) 0.97
Age, years 58.7 ± 12.2 61.2 ± 12.9 0.44
Diabetes 2 (9.1) 6 (10.7) 1.00
Culprit location 0.74
Proximal LAD 15 (68.2) 36 (64.3)
Mid LAD 7 (31.8) 20 (35.7)
Symptom-to-balloon time,
minutes
146.5
(107, 220)
157.5 (129, 210) 0.37
Pre-pPCI TIMI flow 0.66
0/1 15 (68.2) 41 (73.2)
2/3 7 (31.8) 15 (26.8)
Post-pPCI TIMI flow 0.49
2 4 (18.2) 7 (12.5)
3 18 (81.8) 49 (87.5)
Propensity score 0.71 ± 0.15 0.76 ± 0.12 0.19
CMR after pPCI, days 4.6 ± 1.9 4.8 ± 1.5 0.75
Data are shown as n (%), mean ± SD or median (quartile 1, quartile 3). CMR: cardiac
magnetic resonance imaging; PiCSO: Pressure-controlled intermittent Coronary
Sinus Occlusion; pPCI: primary percutaneous coronary intervention; STEMI: ST-
segment elevation myocardial infarction; TIMI: Thrombolysis In Myocardial
Infarction.
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15 s) venous flow is redistributed from normally perfused areas
towards the deprived zones and then reenters the microcirculation[21]. Systolic pressure increase (average maximum during systole
of 70 ± 17 mmHg as seen in this study) in the venous compartment
pushes the blood plasma though the obstructed microcirculatory
bed creating a plasma skimming effect in the venous microcircula-
tion leading to increased perfusion of venules with plasma contain-
ing oxygen and metabolites. While plasma skimming seems to be
one of the central drivers for microcirculatory clearance upon
release of the occlusion [20] the occlusion of the venous outflow
also allows re-distribution of the flow to the deprived perfusion
border zones due to pressure induced vasodilation and increased
collateral flow [21]. Furthermore, aspects of coronary sinus pres-
sure elevation inducing molecular signals have been tested
recently in patients with chronic heart failure indicating that,
beyond salvage, PiCSO may induce regenerative pathways analo-
gous to other methods using mechano-transduction to stimulate
regional molecular pathways [22]. Upon sudden release of the
occlusion, a rapid decline in venous pressure (average pressure
measured during release phase of 13 ± 7 mmHg, creating a gradient
of 57 mmHg; as seen in this study) allows for removal of excessive
myocardial water (edema) and leads to washout of debris and toxic
accumulations from the occlusion site and the impaired microcir-
culation, thus improving flow via culprit lesions towards deprived
myocardium. This release phase lasts approximately 3–4 s. This
novel mechanism of action of the PiCSO Impulse System may
addresses the limitations of the current primary PCI approach, by
clearing the microcirculation thus reducing both ischemia and
reperfusion injury.
Fig. 2. Infarct size in propensity score-matched PiCSO and control patients with
STEMI who underwent pPCI. Error bars show 95% confidence intervals. PiCSO:
Pressure-controlled intermittent Coronary Sinus Occlusion; pPCI: primary percu-
taneous coronary intervention; STEMI: ST-segment elevation myocardial infarction.
Table 2
30-day MACE in PiCSO-treated patients.
MACE/Component n/N (%) 95% CI
30-Day MACE 4/40 10.0%) 2.8%, 23.7%
Cardiac death 3/40 (7.5%) 1.6%, 20.4%
New or worsening heart failure 1/40 (2.5%) 0.0%, 13.2%
Hospitalization for heart failure 0/40 (0.0%) 0.0%, 8.8%
Target vessel revascularization 0/40 (0.0%) 0.0%, 8.8%
Stroke 0/40 (0.0%) 0.0%, 8.8%
Major bleeding 0/40 (0.0%) 0.0%, 8.8%
Coronary sinus damage requiring intervention 0/40 (0.0%) 0.0%, 8.8%
Data are shown as n of total N (%) and 95% Confidence Interval.
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PiCSO
Various animal studies evaluating the PiCSO system have
reported beneficial effects on infarct size [23], microvascular
obstruction and hemorrhagic lesions [24], cardiac function [7,8],
and endothelial tissue structure and mechanics, namely increase
of hemeoxygenase-1 gene expression in the center of infarction
and increase of vascular endothelial growth factor (VEGF) in border
zones [21].
In the Prepare RAMSES study [9], 19 patients with anterior
STEMI underwent pPCI and PiCSO. Compared to matched historical
controls (pPCI alone), there were no significant benefits of PiCSO on
infarct size or LV function. However, PiCSO quantity delivered var-
ied widely between patients in this study, and a significant corre-
lation between PiCSO quantity and infarct size reduction between
over time (r2 = 0.70; p = 0.008). Among patients with PiCSO quan-tities above the median of 494 vs. their matched controls, there
were significant improvements in infarct size reduction from 5 days
to 120 days (41.6% LV mass vs. 27.7% LV mass; p = 0.04).
In the OxAMI-PICSO study [10], 25 patients with anterior STEMI
and an index of microcirculatory resistance (IMR) > 40 who under-
went pPCI and PiCSO were compared with 50 historical controls
with a similar IMR who underwent pPCI alone. PiCSO patients
had a smaller median infarct size at 6 months than controls (26%
vs. 33% LV mass; p = 0.006) [10]. In addition to the infract size
reduction, PiCSO treated patients had on average significantly
lower IMR measured after 24–48 h (24.8 vs. 45.0, p < 0.001). The
responder analysis showed that 90% of PiCSO treated patients
had an IMR less than 40 after 24–48 h while in the control group
only 35.5% managed to get below 40.
Outside of the STEMI setting, in a series of 32 patients after suc-
cessful CRT implantation 8 patients were investigated with PICSO
and 24 patients constituted the controls [22]. To test immediate
molecular responses, in both patient groups, coronary venous
blood samples were taken at baseline and after 20 min, the time
required for the PiCSO intervention. As compared with controls,
significant differential expression of microRNA patterns associated
with cardiac development was observed with PICSO. Co-cultured
post-PICSO sera significantly increased cellular proliferation both
in fibroblasts and adult cardiomyocytes sampled from a transplant
recipient as compared with controls.
The results of these studies, in concert with the present report
suggest that PiCSO treatment as an adjunct to pPCI may not only
reduce infarct size, but also clear the microcirculation by inducing
a mechanochemical feedback loop. The need of such dual pathway
was postulated in a recent review on Optimized Treatment of
ST-Elevation Myocardial Infarction [18]. Authors conclude that
presence and extent of microvascular obstruction represents an
important independent predictor of adverse LV remodeling and
that simultaneously addressing infarct size and microvascular
obstruction may help to translate cardioprotective strategies into
improved clinical outcomes post PCI.4.4. Safety outcomes
The 30-day incidence of MACE in the PiCSO-treated group in the
current study was 10%, concordant with the outcomes in the treat-
ment and control groups from the earlier randomized trials
[11,13–15] (5–11%). Of note, no MACE in the PiCSO group was con-
sidered to be related to the PiCSO procedure or device. The seem-
ingly higher (7.5%, 3/40) 30 days death rate reported in the PiCSO
group is probably only due to coincidence, since in this intent to
treat analysis, one patient did not receive PiCSO treatment due to
difficulties cannulating the coronary sinus, one patient has been
readmitted 23 days post initial PCI with inferior STEMI followed
by cardiogenic shock and one patient developed AF post stenting
followed by cardiogenic shock. In the SWEDEHEART registry [17],
approximately 2.7% STEMI patients are admitted with cardiogenic
shock to the hospital, but these patients have been a priori
excluded from the current study. Nevertheless, SWEDEHEART
authors still report 7.8% in hospital mortality and 9.2% 30 days
mortality post PCI. While none of the above-mentioned deaths
has been adjudicated as related to PiCSO device or procedure we
conclude that the observed death rate in this study is within the
expected range for STEMI patients undergoing PCI.5. Conclusions
In the present propensity score-matched analysis of patients
with anterior STEMI, those who received PiCSO after reperfusion
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trols who underwent pPCI alone. PiCSO therapy was safe, without
specific procedural or device-related adverse effects.
The reduction of ischemic injury by re-distributing blood flow
and the plasma skimming-induced clearance of microvascular
obstruction seen during the PiCSO treatment addresses an unmet
need of additional reduction of infarct size and clearance of
microvascular obstruction, thus positively influencing long-term
cardiac function in STEMI patients. Further adequately powered
randomized controlled studies are warranted to evaluate the
impact of the unique mechanochemical feedback loop induced by
PiCSO treatment.
6. Study limitations
The PiCSO in ACS study was a non-randomized study without a
formal powered hypothesis. Due to the lack of randomization,
PiCSO treated patients and parallel control patients were not well
matched. For this reason, a comparative analysis using propensity
score-matched historical controls was also performed. However,
this non-randomized post-hoc comparison also has limitations,
and residual confounding cannot be excluded.
In INFUSE-AMI all control patients that were used for propen-
sity matching have been treated with bivalirudin According to a
subgroup analysis from the HORIZONS-AMI study bivalirudin does
not seem to influence the infarct size measured by CMR [25]. Fur-
thermore a recent metanalysis showed that compared with hep-
arin, bivalirudin was associated with a similar incidence of
ischemic events following PCI for ACS [26]. A significant associa-
tion of bivalirudin with decreased risk of bleeding was only found
with unbalanced use of GP IIb/IIIa inhibitors in conjunction with
heparin. Further bivalirudin compared with heparin monotherapy
was associated with a similar incidence of all-cause death and
ischemic events after PCI [27].
Since the INFUSE-AMI study has been conducted between 2009
and 2011, 29.6% of patients have been treated with bare-metal
stents and 60% of the patients have received clopidogrel. While
the use of clopidogrel might lead to increased infarct size when
compared to prasugrel or ticagrelor [28], there is no evidence that
use of bare-metal stents, despite all their limitation and increased
risk or restenosis, would negatively impact the infarct size assessed
at 5 days post procedure.Funding
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